Newron Pharmaceuticals S.P.A. Announced earnings results for the half year ended June 30, 2021. For the half year, the company announced total revenue was EUR 2.671 million compared to EUR 2.509 million a year ago. Operating loss was EUR 7.888 million compared to EUR 9.967 million a year ago. Net loss was EUR 9.063 million compared to EUR 10.503 million a year ago. Basic loss per share from continuing operations was EUR 0.51 compared to EUR 0.59 a year ago.